Bressi J C, Verlinde C L, Aronov A M, Shaw M L, Shin S S, Nguyen L N, Suresh S, Buckner F S, Van Voorhis W C, Kuntz I D, Hol W G, Gelb M H
Department of Chemistry, University of Washington, Seattle, WA 98195, USA.
J Med Chem. 2001 Jun 21;44(13):2080-93. doi: 10.1021/jm000472o.
In our continuation of the structure-based design of anti-trypanosomatid drugs, parasite-selective adenosine analogues were identified as low micromolar inhibitors of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Crystal structures of Trypanosoma brucei, Trypanosoma cruzi, Leishmania mexicana, and human GAPDH's provided details of how the adenosyl moiety of NAD(+) interacts with the proteins, and this facilitated the understanding of the relative affinities of a series of adenosine analogues for the various GAPDH's. From exploration of modifications of the naphthalenemethyl and benzamide substituents of a lead compound, N(6)-(1-naphthalenemethyl)-2'-deoxy-2'-(3-methoxybenzamido)adenosine (6e), N(6)-(substituted-naphthalenemethyl)-2'-deoxy-2'-(substituted-benzamido)adenosine analogues were investigated. N(6)-(1-Naphthalenemethyl)-2'-deoxy-2'-(3,5-dimethoxybenzamido)adenosine (6m), N(6)-[1-(3-hydroxynaphthalene)methyl]-2'-deoxy-2'-(3,5-dimethoxybenzamido)adenosine (7m), N(6)-[1-(3-methoxynaphthalene)methyl]-2'-deoxy-2'-(3,5-dimethoxybenzamido)adenosine (9m), N(6)-(2-naphthalenemethyl)-2'-deoxy-2'-(3-methoxybenzamido)adenosine (11e), and N(6)-(2-naphthalenemethyl)-2'-deoxy-2'-(3,5-dimethoxybenzamido)adenosine (11m) demonstrated a 2- to 3-fold improvement over 6e and a 7100- to 25000-fold improvement over the adenosine template. IC(50)'s of these compounds were in the range 2-12 microM for T. brucei, T. cruzi, and L. mexicana GAPDH's, and these compounds did not inhibit mammalian GAPDH when tested at their solubility limit. To explore more thoroughly the structure-activity relationships of this class of compounds, a library of 240 N(6)-(substituted)-2'-deoxy-2'-(amido)adenosine analogues was generated using parallel solution-phase synthesis with N(6) and C2' substituents chosen on the basis of computational docking scores. This resulted in the identification of 40 additional compounds that inhibit parasite GAPDH's in the low micromolar range. We also explored adenosine analogues containing 5'-amido substituents and found that 2',5'-dideoxy-2'-(3,5-dimethoxybenzamido)-5'-(diphenylacetamido)adenosine (49) displays an IC(50) of 60-100 microM against the three parasite GAPDH's.
在我们基于结构设计抗锥虫药物的持续研究中,寄生虫选择性腺苷类似物被鉴定为甘油醛-3-磷酸脱氢酶(GAPDH)的低微摩尔抑制剂。布氏锥虫、克氏锥虫、墨西哥利什曼原虫和人GAPDH的晶体结构提供了NAD(+)的腺苷部分与这些蛋白质相互作用的细节,这有助于理解一系列腺苷类似物对各种GAPDH的相对亲和力。通过对先导化合物N(6)-(1-萘甲基)-2'-脱氧-2'-(3-甲氧基苯甲酰胺基)腺苷(6e)的萘甲基和苯甲酰胺取代基进行修饰探索,研究了N(6)-(取代萘甲基)-2'-脱氧-2'-(取代苯甲酰胺基)腺苷类似物。N(6)-(1-萘甲基)-2'-脱氧-2'-(3,5-二甲氧基苯甲酰胺基)腺苷(6m)、N(6)-[1-(3-羟基萘)甲基]-2'-脱氧-2'-(3,5-二甲氧基苯甲酰胺基)腺苷(7m)、N(6)-[1-(3-甲氧基萘)甲基]-2'-脱氧-2'-(3,5-二甲氧基苯甲酰胺基)腺苷(9m)、N(6)-(2-萘甲基)-2'-脱氧-2'-(3-甲氧基苯甲酰胺基)腺苷(11e)和N(6)-(2-萘甲基)-2'-脱氧-2'-(3,5-二甲氧基苯甲酰胺基)腺苷(11m)相较于6e有2至3倍的改善,相较于腺苷模板有7100至25000倍的改善。这些化合物对布氏锥虫、克氏锥虫和墨西哥利什曼原虫GAPDH的IC(50)在2至12μM范围内,并且在其溶解度极限下测试时不抑制哺乳动物GAPDH。为了更全面地探索这类化合物的构效关系,使用平行溶液相合成法生成了一个包含240个N(6)-(取代)-2'-脱氧-2'-(酰胺基)腺苷类似物的文库,其中N(6)和C2'取代基是根据计算对接分数选择的。这导致又鉴定出40种在低微摩尔范围内抑制寄生虫GAPDH的化合物。我们还探索了含有5'-酰胺基取代基的腺苷类似物,发现2',5'-二脱氧-2'-(3,5-二甲氧基苯甲酰胺基)-5'-(二苯基乙酰胺基)腺苷(49)对三种寄生虫GAPDH的IC(50)为60至100μM。